Project Grant R61CA297882
Award Date
1/2/25
Completion Date
12/31/27
Dollars Obligated
$219K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, NY 10027, USA
Similar Awards
The National Cancer Institute (NCI) awarded Duke University a $387,702 R21 project grant (CFDA 93.396 Cancer Biology Research) to develop an automated bipartite algorithmic pipeline that leverages recent advancements in protein language modeling and co-complex databases to design peptide binders that can induce targeted protein degradation. This "ubiquibody" platform aims to enable the development of protein degraders for intractable cancer targets that are challenging to address...
This $360,100 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development and biological applications of red light bioconjugation and proximity labeling platforms using Os(II) photocatalysts. The key products and services being delivered under this project include: A method for selective bioconjugation of aspartic acid (Asp) and glutamic acid (Glu) residues, where red...
This $169,932 federal Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports the advancement of proteomics technologies for cancer research at the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University. The Principal Investigator (PI), the Technical Director of the Proteomics and Macromolecular Crystallography Shared Resource (PMCSR) at HICCC, aims to enhance the center's capabilities by developing innovative methodologies,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $849,371.00 to support research aimed at "Hijacking Post-Translational Arginylation for Targeted Protein Degradation". The project is focused on developing novel "arginylation targeting chimera" (ARGTACs) technology to leverage the cellular arginylation pathway for targeted degradation of cancer-related proteins. Key aspects of the work include: Establishing the ARGTAC...
The National Cancer Institute (NCI) awarded a $138,489 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the University of California, Irvine. The two-year grant, awarded on September 20, 2025, will fund research focused on developing a "methyl arginine targeting chimera" to induce the lysosomal degradation of intracellular proteins. This novel approach aims to overcome limitations of current protein degradation methods that rely on the proteasomal...
The National Cancer Institute (NCI) awarded a $240,092 Project Grant under the Cancer Biology Research (CFDA 93.396) program to the Scripps Research Institute in La Jolla, California. The grant supports the implementation of a new mass spectrometry-based protein footprinting technique called Covalent Protein Painting (CPP) to measure protein conformations and protein-protein interactions in single cancer cells. The key objectives are to quantify lysine site accessibility in single cells using...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) is supporting the development of tools to enable the rapid, high-sensitivity analysis of changes in protein interactions within one minute or less. The $449,726 award to the University of Illinois will fund the creation of three orthogonal methods that significantly reduce background noise during biotinylation, allowing for the detection of dynamic protein complexes in living cells. The...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $101,856 to The Trustees of Columbia University in the City of New York to conduct research aimed at understanding how genetic variants impact the anti-tumor activity of T cells. The funded project will: Define the mechanisms by which specific PIK3CD genetic variants modulate T cell function and evaluate their in vivo impact in murine models of melanoma and leukemia...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding for researchers at the University of California, San Francisco (UCSF) to develop a new technology called "Structural Surfaceomics" to identify novel immunotherapy targets based on cancer-specific conformations of surface proteins. The $550,255 award, with a performance period from August 1, 2024 to July 31, 2029, supports two key objectives: 1) advancing the Structural...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop effective therapeutic strategies for non-small cell lung cancers with SMARCA4 gene deficiencies. The $557,418 grant, awarded to Columbia University's Health Sciences Division, aims to evaluate the impact of selectively degrading the SMARCA2 protein as a treatment approach for this aggressive lung cancer subtype. The research leverages genetically engineered mouse...